“rare-disease-drugs” Archives

in
Entry Author Date Location
In RNAi Move, Takeda Fronts $300M to Team Up on Arrowhead Liver Drug 10/08/20 National
With Phase 2 Data in Hand, Ovid Eyes Multiple Pivotal Trials for Epilepsy Drug 09/30/20 New York
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D 09/17/20 Boston
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue 09/09/20 National
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases 08/26/20 Boston
Chinook, Aduro Merger Plan Sets Up New Kidney Disease-Focused Biotech 06/02/20 Seattle
Rallybio Lands $145M to Alter Course of FNAIT and More Rare Diseases 05/19/20 New York
Bio Roundup: Acquisitive Alexion, CRISPR on COVID, C. diff Success & More 05/08/20 National
BridgeBio’s Pipeline Expansion Continues as Portfolio’s Milestones Approach 04/30/20 San Francisco
Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More 03/27/20 National
Imara Dives Into Coronavirus-Churned Financial Waters With a $75M IPO 03/12/20 Boston
Acceleron Drops Drug for Rare Muscle Disease After Mixed Phase 2 Data 03/10/20 Boston
Spruce Bio Raises $88M for Clinical Tests of Rare Endocrine Disease Drug 02/20/20 San Francisco
Imara Reveals IPO Plan as Sickle Cell Drug Advances in the Clinic 02/18/20 Boston
FDA Flags Risk of Infection, Kidney Damage for Sarepta Duchenne Drugs 01/22/20 Boston
Apellis Rare Blood Disease Drug Tops Alexion’s in Head-to-Head Test 01/07/20 Boston
FDA Puts Partial Hold on Tests of Ipsen Drug Acquired in $1B Deal 12/06/19 National
Alnylam Gets Quick FDA OK for Second RNAi Rare Disease Drug 11/20/19 Boston
FDA Halts Novartis Gene Therapy Study Amid Animal Safety Concerns 10/30/19 National
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More 10/18/19 National
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma 10/10/19 Boston
Dova Pharmaceuticals Agrees to Sobi Acquisition, Shares Jump 38% 09/30/19 Raleigh Durham
Akcea Shakes Up Management and Shows Three Executives the Door 09/23/19 Boston
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs 08/16/19 New York
Rhythm Pharma’s Obesity Drug Hits Phase 3 Goals, FDA Filing Planned 08/07/19 Boston
BridgeBio Upsizes IPO to $348M, Topping Adaptive’s Wall Street Debut 06/27/19 San Francisco
Stoke Therapeutics Upsizes IPO, Raises $142M for Dravet Drug R&D 06/18/19 Boston
Bio Roundup: Opioids in Court, IPO Parade, Brain Cancer Bet & More 05/31/19 National
The Biotech IPO Queue Grows Longer as Five More Companies File 05/28/19 National
Stoke Therapeutics Preps IPO to Bring Dravet Syndrome Drug to Clinic 05/24/19 Boston
Page 1 of 3 next page »